» Authors » Daan Muilwijk

Daan Muilwijk

Explore the profile of Daan Muilwijk including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 35
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
van Deutekom J, Beekman C, Bijl S, Bosgra S, van den Eijnde R, Franken D, et al.
Nucleic Acid Ther . 2023 Apr; 33(3):193-208. PMID: 37036788
In the last two decades, antisense oligonucleotides (AONs) that induce corrective exon skipping have matured as promising therapies aimed at tackling the dystrophin deficiency that underlies the severe and progressive...
2.
van de Steeg E, Lappchen T, Aguilera B, Jansen H, Muilwijk D, Vermue R, et al.
Nucleic Acid Ther . 2017 Apr; 27(4):221-231. PMID: 28418733
Antisense oligonucleotides (AONs) are promising candidates for treatment of Duchenne muscular dystrophy (DMD), a severe and progressive disease resulting in premature death. However, more knowledge on the pharmacokinetics of new...
3.
Jirka S, Heemskerk H, Winter C, Muilwijk D, Pang K, de Visser P, et al.
Nucleic Acid Ther . 2013 Dec; 24(1):25-36. PMID: 24320790
Antisense oligonucleotide (AON)-mediated exon skipping is a promising therapeutic approach for Duchenne muscular dystrophy that is currently being tested in various clinical trials. This approach is based on restoring the...
4.
Scheffelaar R, Paravidino M, Muilwijk D, Lutz M, Spek A, de Kanter F, et al.
Org Lett . 2008 Dec; 11(1):125-8. PMID: 19053816
Isocyano dihydropyridones accessible via a recently reported multicomponent reaction react with aldehydes and amines to afford dihydrooxazolopyridines in high yield. The scope and limitations of this novel multicomponent reaction were...